Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects

Medical Science Monitor

Volumn 15, Issue 9, 2009, Pages

  Cable, David George ^a   Celotto, Andrea Carla ^b   Evora, Paulo Roberto Barbosa ^b,c   Schaff, Hartzell Vernon ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

ADMA; Asymmetric dimethylarginine; Endothelium; Nitric oxide; Nitric oxide synthase

Indexed keywords

ACETYLCHOLINE; ARGININE; CALCIMYCIN; CALCIUM IONOPHORE; DEXTRO ARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; NORADRENALIN; PROSTAGLANDIN F2 ALPHA;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; BLOOD VESSEL REACTIVITY; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY; DOG; ENZYME INHIBITION; FEMORAL ARTERY; NONHUMAN; RENAL ARTERY; VASCULAR ENDOTHELIUM;

ANIMALS; ARGININE; ARTERIES; DOGS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; TISSUE CULTURE TECHNIQUES;

EID: 70349914397     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ghosh SK, Paik WK, Kim S: Purification and molecular identification of two protein methylases I from calf brain. Myelin basic protein- and histone-specific enzyme. J Biol Chem, 1988; 263: 19024-19033
2. Tang J, Frankel A, Cook RJ et al: PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem, 2000; 275: 7723-7730 (Pubitemid 30159676)
3. Leiper JM, Santa Maria J, Chubb A et al: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J, 1999; 343: 209-214 (Pubitemid 29473897)
4. Ogawa T, Kimoto M, Sasaoka K: Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun, 1987; 148: 671-677
5. Vallance P, Leone A, Calver A et al: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 1992; 339: 572-575
6. Kaiser L, Tithof PK, Williams JF: Depression of endothelium-dependent relaxation by filarial parasite products. Am J Physiol, 1990; 259: H648-52 (Pubitemid 20259446)
7. Pearson PJ, Schaff HV, Vanhoutte PM: Acute impairment of endothelium- dependent relaxations to aggregating platelets following reperfusion injury in canine coronary arteries. Cardiovasc Res, 1990; 67: 385-393
8. Luscher TF, Diederich D, Siebenmann R et al: Difference between endothelium- dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med, 1988; 319: 462-467 (Pubitemid 18205550)
9. Kakimoto Y, Akazawa S: Isolation and identification of N-G,N-G- and N-G,N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem, 1970; 245: 5751-5758
10. Park KS, Lee HW, Hong SY et al: Determination of methylated amino acids in human serum by high-performance liquid chromatography. J Chromatogr, 1988; 440: 225-230 (Pubitemid 18128178)
11. Feng Q, Lu X, Fortin AJ et al: Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res, 1998; 37: 667-675 (Pubitemid 28231161)
12. Boger RH, Bode-Boger SM, Sydow K et al: Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol, 2000; 20: 1557-1564 (Pubitemid 30353888)
13. Morris ST, McMurray JJ, Spiers A, Jardine AG: Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int, 2001; 60: 1077-1082 (Pubitemid 34205807)
14. Segarra G, Medina P, Ballester RM et al: Effects of some guanidino compounds on human cerebral arteries. Stroke, 1999; 30: 2206-2211 (Pubitemid 29473272)
15. Jin JS, D'Alecy LG: Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol, 1996; 28: 439-446
16. Cardounel AJ, Cui H, Samouilov A et al: Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem, 2007; 282: 879-887 (Pubitemid 47076535)
17. Cable DG, Sorajja P, Oeltjen MR, Schaff HV: Different effects of protamine on canine coronary microvessel and conductance arteries: evidence of hyperpolarizing factor release. Surgery, 1999; 126: 835-841 (Pubitemid 29523321)
18. Vallance P, Leiper J: Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol, 2004; 24: 1023-1030 (Pubitemid 38737826)
19. Clarke S: Protein methylation. Curr Opin Cell Biol, 1993; 5: 977-983
20. McBride AE, Silver PA: State of the arg: protein methylation at arginine comes of age. Cell, 2001; 106: 5-8
21. Evora PR, Pearson PJ, Schaff HV: Impaired endothelium-dependent relaxation after coronary reperfusion injury: evidence for G-protein dysfunction. Ann Thorac Surg, 1994; 57: 1550-1556
22. Boger RH: Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med (London, England), 2005; 10(Suppl.1): S19-25
23. Beltowski J, Kedra A: Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep, 2006; 58: 159-178 (Pubitemid 43757435)